Phase I trial of nedaplatin and S-1 in patients with advanced squamous cell lung cancer.

Cancer shared this article with you from Inoreader Phase I trial of nedaplatin and S-1 in patients with advanced squamous cell lung cancer. Via Clinical Lung Cancer Authors: Kanaji N, Ishii T, Ueda Y, Ichikawa H, Kishimoto N, Kadowaki N Abstract The platinum doublet is considered to be the standard cytotoxic chemotherapy for advanced lung cancer. It has been previously reported that nedaplatin and S-1 have clinical efficacy against squamous cell lung cancer. As the combination of nedaplatin and S-1 has never been studied for advanced squamous cell lung cancer, a phase I trial of this combination in the first-line setting was conducted. Patients who had not received chemotherapy previously, aged ≤75 years and with advanced squamous cell lung cancer were recruited. Nedaplatin was administered intravenously (day 1), and S-1 was orally administered (days 1-14) at a fixed dose based on the body surface area (BSA) <1.25 m2, 80 mg/day; BSA=1.25-... View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.